Low-molecular weight advanced glycation end products: Markers of tissue AGE accumulation and more?

Annals of the New York Academy of Sciences

Volumn 1043, Issue , 2005, Pages 644-654

  Thomas, Merlin C ^a   Forbes, Josephine M ^a   MacIsaac, Richard ^b   Jerums, George ^b   Cooper, Mark E ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Advanced glycation end products (AGEs); Anemia; Diabetes; Diabetic nephropathy; Fluorescence

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMINOGUANIDINE; BIOLOGICAL MARKER; IMIDAZOLE; PENTOSIDINE;

BIOACCUMULATION; CONFERENCE PAPER; DIABETES MELLITUS; DIGESTION; DISEASE DURATION; FLUORESCENCE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; KIDNEY INJURY; MOLECULAR WEIGHT; NONHUMAN; PROTEIN MODIFICATION; RENAL PROTECTION; ULTRAFILTRATION;

EID: 23744445579     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1333.073     Document Type: Conference Paper

References (41)

1. VLASSARA, H. 2001. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab. Res. Rev. 17: 436-443.
2. WALTON, H.A., J. BYRNE & G.B. ROBINSON. 1992. Studies of the permeation properties of glomerular basement membrane: cross-linking renders glomerular basement membrane permeable to protein. Biochim. Biophys. Acta 1138: 173-183.
3. SILBIGER, S., S. CROWLEY, Z. SHAN, et al. 1993. Nonenzymatic glycation of mesangial matrix and prolonged exposure of mesangial matrix to elevated glucose reduces collagen synthesis and proteoglycan charge. Kidney Int. 43: 853-864.
4. RAABE, H.M., J.H. HOPNER, H. NOTBOHM, et al. 1998. Biochemical and biophysical alterations of the 7S and NC1 domain of collagen IV from human diabetic kidneys. Diabetologia 41: 1073-1079.
5. MOTT, J.D., R.G. KHALIFAH, H. NAGASE, et al. 1997. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int. 52: 1302-1312.
6. TARSIO, J.F., B. WIGNESS, T.D. RHODE, et al. 1985. Nonenzymatic glycation of fibronectin and alterations in the molecular association of cell matrix and basement membrane components in diabetes mellitus. Diabetes 34: 477-484.
7. THORNALLEY, P.J., M. WESTWOOD, T.W. Lo & A.C. MCLELLAN. 1995. Formation of methylglyoxal-modified proteins in vitro and in vivo and their involvement in AGE-related processes. Contrib. Nephrol. 112: 24-31.
8. BROWNLEE, M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
9. SHRINGARPURE, R., T. GRUNE, J. MEHLHASE, & K.J. DAVIES. 2003. Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J. Biol. Chem. 278: 311-318.
10. DAVIES, K.J. 2001. Degradation of oxidized proteins by the 20S proteasome. Biochimie 83: 301-310.
11. THORNALLEY, P.J., S. BATTAH, N. AHMED, et al. 2003. Quantitative screening of advanced glycation end products in cellular and extracellular proteins by tandem mass spectrometry. Biochem. J. 375: 581-592.
12. DEUTHER-CONRAD, W., S. FRANKE, M. SOMMER, et al. 2001. Differences in the modulating potential of advanced glycation end product (AGE) peptides versus AGE proteins. Kidney Int. Suppl. 78: S63-S66.
13. VERZOLA, D., M.B. BERTOLOTTO, B. VILLAGGIO, et al. 2004. Oxidative stress mediates apoptotic changes induced by hyperglycemia in human tubular kidney cells. J. Am. Soc. Nephrol. 15: S85-S87.
14. GUGLIUCCI, A. & M. BENDAYAN. 1996. Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 39: 149-160.
15. ASANO, M., Y. FUJITA, Y. UEDA, et al. 2002. Renal proximal tubular metabolism of protein-linked pentosidine, an advanced glycation end product. Nephron 91: 688-694.
16. SAITO, A., R. NAGAI, A. TANUMA, et al. 2003. Role of megalin in endocytosis of advanced glycation end products: implications for a novel protein binding to both megalin and advanced glycation end products. J. Am. Soc. Nephrol. 14: 1123-1131.
17. YOUSSEF, S., D.T. NGUYEN, T. SOULIS, et al. 1999. Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. Kidney Int. 55: 907-916.
18. RAJ, D.S., D. CHOUDHURY, T.C. WELBOURNE & M. LEVI. 2000. Advanced glycation end products: a nephrologist's perspective. Am. J. Kidney Dis. 35: 365-380.
19. MONNIER, V.M., V. VISHWANATH, K.E. FRANK, et al. 1986. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N. Engl. J. Med. 314: 403-408.
20. MEERWALDT, R., R. GRAAFF, P.H. OOMEN, et al. 2004. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 47: 1324-1330.
21. KESSEL, L., J.L. HOUGAARD, B. SANDER, et al. 2002. Lens ageing as an indicator of tissue damage associated with smoking and non-enzymatic glycation-a twin study. Diabetologia 45: 1457-1462.
22. MAKITA, Z., R. BUCALA, E.J. RAYFIELD, et al. 1994. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343: 1519-1522.
23. SOULIS-LIPAROTA, T., M.E. COOPER, M. DUNLOP & G. JERUMS. 1995. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 38: 387-394.
24. STITT, A.W. 2003. The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp. Mol. Pathol. 75: 95-108.
25. RUMBLE, J.R., M.E. COOPER, T. SOULIS, et al. 1997. Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products. J. Clin. Invest. 99: 1016-1027.
26. VLASSARA, H., L.J. STRIKER, S. TEICHBERG, et al. 1994. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc. Natl. Acad. Sci. USA 91: 11704-11708.
27. VALENCIA, J.V., S.C. WELDON, D. QUINN, et al. 2004. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Anal. Biochem. 24: 68-78.
28. AGALOU, S., N. AHMED, A. DAWNAY & P.J. THORNALLEY. 2003. Removal of advanced glycation end products in clinical renal failure by peritoneal dialysis and haemodialysis. Biochem. Soc. Trans. 31: 1394-1396.
29. MIURA, J., S. YAMAGISHI, Y. UCHIGATA, et al. 2003. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J. Diabetes Complications 17: 16-21.
30. MIYATA, T., Y. UEDA, K. HORIE, et al. 1998. Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int. 53: 416-422.
31. THOMAS, M.C., C. TIKELLIS, P. KANTHARIDIS, et al. 2004. The role of advanced glycation in reduced organic cation transport associated with experimental diabetes. J. Physiol. Exp. Ther. 311: 456-466.
32. THOMAS, M.C., C. TSALAMANDRIS, R. MACISAAC, et al. 2004. Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. Kidney Int. 66: 1167-1172.
33. PAPANASTASIOU, P., L. GRASS, H. RODELA, et al. 1994. Immunological quantification of advanced glycation end products in the serum of patients on hemodialysis or CAPD. Kidney Int. 46: 216-222.
34. LI, Y.M., M. STEFFES, T. DONNELLY, et al. 1996. Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc. Natl. Acad. Sci USA 93: 3902-3907.
35. GONZALEZ-ALBARRAN, O., O. GOMEZ, E. RUIZ, et al. 2003. Role of systolic blood pressure on the progression of kidney damage in an experimental model of type 2 diabetes mellitus, obesity, and hypertension (Zucker rats). Am. J. Hypertens. 16: 979-985.
36. MOHANRAM, A. & R.D. TOTO. 2003. Outcome studies in diabetic nephropathy. Semin. Nephrol. 23: 255-271.
37. KEANE, W.F. & P.A. LYLE; REDUCTION OF ENDPOINTS IN NIDDM WITH THE ANGIOTENSIN II RECEPTOR ANTAGONIST LOSARTAN STUDY. 2003. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study. Am. J. Kidney Dis. 41(3 Suppl. 1): S22-S25.
38. SHARP, P.S., S. RAINBOW & S. MUKHERJEE. 2003. Serum levels of low molecular weight advanced glycation end products in diabetic subjects. Diabet. Med. 20: 575-579.
39. BEISSWENGER, P.J., Z. MAKITA, T.J. CURPHEY, et al. 1995. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 44: 824-829.
40. KIUCHI, K., J. NEJIMA, T. TAKANO, et al. 2001 Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart 85: 87-91.
41. SCHWENGER, V., M. ZEIER, T. HENLE & E. RITZ. 2001. Advanced glycation endproducts (AGEs) as uremic toxins. Nahrung 45: 172-176.